一个现实世界的经验与Resmetirom:耐受性和访问
Sameera Shuaibi1, Ian Tobal1, James Gore1
1Department of Internal Medicine, Ochsner Health, New Orleans, Louisiana.
Gastro hep advances
|July 21, 2025
概括
雷斯米蒂罗姆在与代谢功能障碍相关的脂肪肝炎 (MASH) 纤维化治疗中表现出良好的耐受性. 虽然大多数患者获得了保险批准,但延迟和测试要求给访问带来了挑战.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 代谢功能障碍相关的脂肪肝炎 (MASH) 是一种进展性肝病.
- Resmetirom是FDA批准的MASH的第一个治疗方法.
- 评估resmetirom的耐受性和获取性对于患者护理至关重要.
研究的目的:
- 在3个月内评估MASH患者的resmetirom耐受性.
- 确定影响药物获取的因素,包括保险和发行.
- 分析治疗结果和不良事件.
主要方法:
- 对113名MASH患者的回顾性图表审查,这些患者接受了至少3个月的resmetirom治疗.
- 收集了关于耐受性,不良反应,肝酶,保险覆盖和发药延迟的数据.
- 分析患者的结果和药物坚持.
主要成果:
- 雷斯梅西罗姆的耐受性很好,停药率很低 (8.8%).
- 常见的副作用包括恶心,吐和腹 (每个为12.4%).
- 肝酶 (AST,ALT,ALP) 在治疗3个月后出现下降.
- 24.1%的患者需要保险上诉,93.4%的患者最终获得批准.
- 经批准后处方填充的平均延迟为12.5天.
结论:
- 在短期内,resmetirom是一种安全且耐受良好的MASH治疗方法.
- 保险批准通常是可以实现的,但上诉和发放延迟是常见的.
- 侵入性纤维化检测可能需要获得保险批准,这会影响及时获取.
更多相关视频
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
305
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
305
01:19Pharmacovigilance
996
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
996
01:11Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
01:16Bioequivalence: Overview
1.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.2K
01:16Insulin: Dosing Regimen and Adverse Effects
262
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
262